CNTX

Context Therapeutics Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.31
52-Week Range: $0.30 – $3.62
Market Cap: $28.45M
P/E (TTM): —
EPS (TTM): -0.48
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.75
PEG Ratio: —
Return on Equity: -76.14%
Return on Assets: -45.70%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 5.81
Debt/Equity: 0.01
Total Debt: $244.99K
Free Cash Flow: $-31.53M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-14.29M

CNTX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$7.09M	$17.78M	$22.70M	$31.86M
Selling, General & Admin	$7.79M	$7.29M	$7.22M	$7.85M
Operating Expenses	$14.88M	$25.07M	$29.92M	$39.70M
Operating Income	-$14.88M	-$25.07M	-$29.92M	-$39.70M
EBITDA	-$14.87M	-$25.06M	-$29.91M	-$39.69M
Pretax Income	-$14.84M	-$23.96M	-$26.73M	-$36.12M
Net Income	-$14.84M	-$23.96M	-$26.73M	-$36.12M
Diluted EPS	-0.93	-1.50	-0.46	-0.38
Diluted Shares	15.97M	15.97M	58.42M	95.19M

CNTX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$35.50M	$14.45M	$94.43M	$66.00M
Current Assets	$37.85M	$16.05M	$97.90M	$68.35M
Total Assets	$37.97M	$16.06M	$98.13M	$68.49M
Current Liabilities	$3.21M	$4.19M	$2.75M	$8.02M
Total Debt	$55.08K	$0.00	$219.38K	$112.06K
Total Liabilities	$3.21M	$4.19M	$2.86M	$8.02M
Retained Earnings	-$44.09M	-$68.05M	-$94.78M	-$130.90M
Shareholders' Equity	$34.76M	$11.87M	$95.27M	$60.47M
Working Capital	$34.65M	$11.86M	$95.15M	$60.33M

CNTX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$13.55M	-$21.05M	-$14.56M	-$26.39M
Capital Expenditure	-$536.84K	—	-$14.76M	-$2.03M
Free Cash Flow	-$14.09M	-$21.05M	-$29.31M	-$28.42M
Depreciation & Amortisation	$9.27K	$12.04K	$10.88K	$16.25K
Stock-Based Compensation	$976.44K	$1.08M	$841.87K	$1.33M
Investing Cash Flow	-$536.84K	$0.00	-$14.76M	-$2.03M
Financing Cash Flow	-$102.07K	$0.00	$109.29M	-$15.27K
Net Change in Cash	-$14.19M	-$21.05M	$79.98M	-$28.43M

CNTX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.46M	$7.83M	$8.72M	$11.84M	$7.02M	$12.53M
Selling, General & Admin	$2.07M	$1.93M	$1.89M	$1.96M	$2.33M	$2.44M
Operating Expenses	$5.53M	$9.76M	$10.61M	$13.80M	$9.34M	$14.97M
Operating Income	-$5.53M	-$9.76M	-$10.61M	-$13.80M	-$9.34M	-$14.97M
EBITDA	-$5.53M	-$9.75M	-$10.61M	-$13.80M	-$9.34M	-$14.96M
Pretax Income	-$4.58M	-$8.83M	-$9.69M	-$13.03M	-$8.68M	-$14.56M
Net Income	-$4.58M	-$8.83M	-$9.69M	-$13.03M	-$8.68M	-$14.56M
Diluted EPS	-0.05	-0.09	-0.10	—	-0.09	-0.15
Diluted Shares	95.19M	95.19M	95.19M	—	95.18M	95.18M

CNTX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$89.35M	$83.52M	$76.94M	$66.00M	$54.53M	$42.99M
Current Assets	$92.73M	$86.95M	$79.06M	$68.35M	$58.52M	$45.82M
Total Assets	$92.97M	$87.15M	$79.23M	$68.49M	$58.86M	$46.13M
Current Liabilities	$1.90M	$4.56M	$6.04M	$8.02M	$6.53M	$7.88M
Total Debt	$193.71K	$167.32K	$140.20K	$112.06K	$282.42K	$244.99K
Total Liabilities	$1.98M	$4.61M	$6.06M	$8.02M	$6.66M	$7.96M
Retained Earnings	-$99.36M	-$108.18M	-$117.88M	-$130.90M	-$139.58M	-$154.14M
Shareholders' Equity	$90.98M	$82.54M	$73.17M	$60.47M	$52.20M	$38.17M
Working Capital	$90.83M	$82.39M	$73.02M	$60.33M	$51.98M	$37.93M

CNTX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$5.03M	-$5.84M	-$6.58M	-$8.94M	-$11.43M	-$7.02M
Capital Expenditure	-$33.95K	—	—	-$2.00M	-$37.26K	-$4.52M
Free Cash Flow	-$5.06M	-$5.84M	-$6.58M	-$10.94M	-$11.47M	-$11.54M
Depreciation & Amortisation	$4.05K	$4.07K	$4.07K	$4.07K	$4.69K	$6.65K
Stock-Based Compensation	$293.72K	$389.11K	$323.08K	$325.17K	$409.22K	$528.10K
Investing Cash Flow	-$33.95K	$0.00	$0.00	-$2.00M	-$37.26K	-$4.52M
Financing Cash Flow	-$15.27K	$0.00	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	-$5.08M	-$5.84M	-$6.58M	-$10.94M	-$11.47M	-$11.54M

Market Snapshot

About

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for solid tumors, particularly those affecting women. Headquartered in Philadelphia, Pennsylvania, the company focuses on identifying and developing therapies that target specific molecular profiles of cancers. Context Therapeutics' lead program, CTIM-76, is a Claudin 6 (CLDN6)-targeted antibody-drug conjugate being developed for CLDN6-positive solid tumors including ovarian, endometrial, and testicular cancers. The company uses proprietary biomarker-driven approaches to identify patient populations most likely to benefit from its therapies. Context Therapeutics aims to advance precision oncology by developing targeted treatments that address significant unmet needs in cancers with limited treatment options.